David A de la Garza-Kalife1, Verónica L Loaiza-Gutiérrez1, Esther Alhelí Hernández-Tobías2, Carlos A González-Villarreal3, Jose Francisco Islas1, Michelle G Santoyo-Suárez1, Elsa N Garza-Treviño1,*, Paulina Delgado-Gonzalez1,*
Oncology Research, Vol.33, No.9, pp. 2243-2262, 2025, DOI:10.32604/or.2025.065222
- 28 August 2025
Abstract Emerging evidence highlights the potential of bioactive compounds, particularly polyphenols, as adjunctive therapeutic agents in the treatment of pancreatic cancer (PC), one of the most aggressive malignancies. This review focuses on epigallocatechin gallate (EGCG) and resveratrol due to their extensively documented anticancer activity, favorable safety profiles, and their unique ability to modulate multiple signaling pathways relevant to pancreatic tumorigenesis. Among polyphenols, these two have shown superior anti-cancer activity, epigenetic regulatory effects, and synergy with standard chemotherapies in preclinical pancreatic cancer models. Resveratrol exhibits anti-proliferative effects by modulating key signaling pathways, including phosphatidylinositol 3 kinase (PI3K)/protein… More >
Graphic Abstract